Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
Yuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

Antibodies to watch in 2024
Silvia Crescioli, Hélène Kaplon, Alicia M. Chenoweth, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 83
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 35
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Weishi Cheng, Kai Kang, Ailin Zhao, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 25
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Recent advances and future strategies in first-line treatment of ES-SCLC
Igor Gómez‐Randulfe, Rita Leporati, B. K. Gupta, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113581-113581
Open Access | Times Cited: 8
STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance
Tianye Li, Weijiang Zhang, Mengke Niu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy
Lei Liu, Genwang Chen, Sisi Gong, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Xue Ying, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy
Jiacheng Lyu, Lin Bai, Yumiao Li, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Efficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis
Xin Yan, Suhua Chen, Guisen Dai, et al.
Tumori Journal (2025)
Closed Access
Meta-Analysis of Clinical Trial on the Comparative Efficacy and Safety Profiles of Immunotherapeutic Strategies in Cervical Cancer
V Navya, Ravindra Kumar
Critical Reviews in Oncology/Hematology (2025), pp. 104673-104673
Closed Access
The role of the TREM receptor family in cardiovascular diseases: Functions, mechanisms, and therapeutic target
Jin-Yi Xue, Mingtai Chen, Y Jian, et al.
Life Sciences (2025) Vol. 369, pp. 123555-123555
Closed Access
Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4; a mini review
Amirhossein Mardi, Leili Aghebati‐Maleki
Human Antibodies (2025)
Closed Access
Iparomlimab and Tuvonralimab: First Approval
Susan J. Keam
Drugs (2025)
Closed Access
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study
Yan Huang, Yunpeng Yang, Yuanyuan Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review
Jiamin Xu, Shukun Mu, Yun Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer
Marco Siringo, Javier Baena, Helena Bote de Cabo, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5505-5505
Open Access | Times Cited: 4
IER5L is a Prognostic Biomarker in Pan-Cancer Analysis and Correlates with Immune Infiltration and Immune Molecules in Non-Small Cell Lung Cancer
Xin Chen, Yan‐qiu He, Ti‐wei Miao, et al.
International Journal of General Medicine (2023) Vol. Volume 16, pp. 5889-5908
Open Access | Times Cited: 2
Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer
Zeyu Zhang, Xueyan Geng, Maopeng Yin, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
Dandan Song, Shufu Hou, Ning Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Feng Bi, Jian Dong, Chuan Jin, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
Dan-Yun Ruan, Xiao-Li Wei, Furong Liu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access
Research Progress of Immunotherapy in the Treatment of Advanced or Recurrent Cervical Cancer
嘉欣 马
Advances in Clinical Medicine (2024) Vol. 14, Iss. 12, pp. 1550-1558
Closed Access
Immunological assessment of recent immunotherapy for colorectal cancer.
Subhadeep Das, Diptikanta Acharya
Research Square (Research Square) (2023)
Open Access
Immunological Assessment of Recent Immunotherapy for Colorectal Cancer
Subhadeep Das, Diptikanta Acharya
Immunological Investigations (2023) Vol. 52, Iss. 8, pp. 1065-1095
Open Access
Page 1

Scroll to top